BRIEF—Opdivo gets NHS funding for use post-surgery in specific urothelial cancer patients

US pharma major Bristol Myers Squibb has announced that the National Institute for Health and Care Excellence (NICE), the cost-effectiveness watchdog for England and Wales, has issued a new Final Appraisal Document (FAD) relating to Opdivo (nivolumab).

The FAD recommends the use of the immuno-oncology drug for the adjuvant treatment of adult patients with muscle invasive urothelial carcinoma, who are at high risk of recurrence following radical surgical resection, and whose tumors express PD-L1 at a level of 1% or more.

Opdivo is recommended only if adjuvant treatment with platinum-based chemotherapy is unsuitable.